ReviewWorld journal of oncology2023
Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Cancer Antigen 125, Prostate-Specific Antigen and Other Cancer Markers: A Primer on Commonly Used Cancer Markers.
Review in World journal of oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- The specificity trap in routine tumor biomarker interpretation: Advancing the 3PM-based clinical decision framework to benefits of patients.The EPMA journal · 2026Review
- Nano-biosensors for circulating tumor markers: advancing liquid biopsy toward precision cancer diagnostics.Journal of cancer research and clinical oncology · 2026Review
- HuNT: A Reference Transcriptome Atlas for Human Normal Tissues.Phenomics (Cham, Switzerland) · 2026Article
- Serum levels of immunoglobulins, tumour markers, and chemokines in gastric cancer patients treated with SOX regimen versus oxaliplatin monotherapy.Journal of medical biochemistry · 2026Article
- A sensitive and cost-effective "turn-on" aptasensor for carcinoembryonic antigen using Ce-UiO-66 as an ultraefficient nanoquencher.Mikrochimica acta · 2026Article
- Cell surface oncofetal antigens in prostate cancer: therapeutic potential and radioligand targeting.EJNMMI research · 2026Review
- Prognostic Value of Albumin-to-CEA Ratio in Metastatic Colorectal Cancer: A Retrospective Study.Biomedicines · 2026Article
- Graph Neural Networks Reveal Candidate Protein Biomarkers Underlying Abdominal Aortic Aneurysm Biology.Computational and structural biotechnology journal · 2026Article
- Strategy for early diagnosis of pancreatic cancer.Frontiers in gastroenterology (Lausanne, Switzerland) · 2026Review
- Circulating tumor DNA informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers.Cancer · 2026Article
- Diagnostic Value of CA-125 and Other Tumor Biomarkers in Children with Suspected Malignancy: A Retrospective Cohort Study.Diagnostics (Basel, Switzerland) · 2025Article
- Molecular docking insights into miR-155 and VEGF synergy: colorectal cancer detection through AI-enhanced integration of molecular biomarkers and clinical risk assessment.European journal of medical research · 2025Article
- Emerging technologies and clinical translation of urine-based liquid biopsy in urological cancers.Genes & genomics · 2025Review
- Engineering Pt Single-Atom Doped SeSSmall methods · 2025Article
- Article
- Plasma Protein Biomarkers to Detect Early Gastric Preneoplasia and Cancer: A Prospective Study.International journal of molecular sciences · 2025Article
- Review
- Therapeutic Opportunities in Melanoma Through PRAME Expression.Biomedicines · 2025Review
- Artificial intelligence prediction of carcinoembryonic antigen structure and interactions relevant for colorectal cancer.Biochemistry and biophysics reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer markers are molecules produced by cancer cells which may serve to identify the presence of cancer. Cancer markers can be differentiated as serum-based, radiology-based and tissue-based, and are one of the most important tools in diagnosing, staging and monitoring of treatment of many cancers. The most used cancer markers are serum cancer markers due to its relative ease and lower cost of testing. However, serum cancer markers have poor mass screening utilization due to poor positive predictive value. Several markers such as prostate-specific antigen (PSA), beta-human chorionic gonadotropin (B-hCG), alpha-fetoprotein (AFP), and lactate dehydrogenase (LDH) are used to aid in diagnosis of cancer in cases of high suspicion. Serum markers such as carcinoembryonic antigen (CEA), AFP, carbohydrate antigen 19-9 (CA 19-9), and 5-hydroxyindoleacetic acid (5-HIAA) play a significant role in assessing disease prognosis as well as response to treatment. This work reviews the role of some of the biomarkers in the diagnosis and treatment of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.